PAVmed (PAVM) 10-Q 14 Aug 20 2020 Q2 Quarterly report Financial data

Document and Entity Information

Document and Entity Information - shares	6 Months Ended
	Jun. 30, 2020	Aug. 11, 2020
Cover [Abstract]
Entity Registrant Name	PAVmed Inc.
Entity Central Index Key	0001624326
Document Type	10-Q
Document Period End Date	Jun. 30, 2020
Amendment Flag	false
Current Fiscal Year End Date	--12-31
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business Flag	true
Entity Emerging Growth Company	true
Entity Ex Transition Period	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		49,638,690
Document Fiscal Period Focus	Q2
Document Fiscal Year Focus	2020

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets - USD ($) $ in Thousands	Jun. 30, 2020	Dec. 31, 2019
Current assets
Cash	$ 7,080	$ 6,219
Prepaid expenses and other current assets	1,074	328
Total current assets	8,154	6,547
Other assets	728	693
Total assets	8,882	7,240
Current liabilities
Accounts payable	3,646	2,353
Accrued expenses and other current liabilities	1,541	1,386
Current portion - Cares Act Paycheck Protection Program note payable	150
Senior Secured Convertible Notes - at fair value	12,300	8,139
Senior Convertible Note - at fair value	3,900
Total current liabilities	21,537	11,878
Cares Act Paycheck Protection Program note payable	150
Total liabilities	21,687	11,878
COMMITMENTS AND CONTINGENCIES (NOTE 7)
Stockholders' Equity (Deficit)
Common stock, par value $0.001; 150,000 shares authorized; 47,919 and 40,479 shares issued and outstanding as of March 31, 2020 and December 31, 2019, respectively	48	41
Additional paid-in capital	60,147	47,554
Accumulated deficit	(73,908)	(53,715)
Total PAVmed Inc. Stockholders' Deficit	(11,320)	(3,824)
Noncontrolling interest	(1,485)	(814)
Total Stockholders' Deficit	(12,805)	(4,638)
Total Liabilities and Equity (Deficit)	8,882	7,240
Series B Convertible Preferred Stock [Member]
Stockholders' Equity (Deficit)
Preferred stock, par value $0.001, 20,000 shares authorized;	$ 2,393	$ 2,296

Condensed Consolidated Balanc_2

Condensed Consolidated Balance Sheets (Parenthetical) - $ / shares	Jun. 30, 2020	Dec. 31, 2019
Preferred stock, par value	$ 0.001	$ 0.001
Preferred stock, shares authorized	20,000,000	20,000,000
Common stock, par value per share	$ 0.001	$ 0.001
Common stock, shares authorized	150,000,000	150,000,000
Common stock, shares issued	47,919,000	40,479,000
Common stock, shares outstanding	47,919,000	40,479,000
Series B Convertible Preferred Stock [Member]
Preferred stock, par value	$ 0.001	$ 0.001
Preferred stock, shares issued	1,180,000	1,158,000
Preferred stock, shares outstanding	1,180,000	1,158,000

Condensed Consolidated Statemen

Condensed Consolidated Statements of Operations (Unaudited) - USD ($) shares in Thousands, $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2020	Jun. 30, 2019	Jun. 30, 2020	Jun. 30, 2019
Income Statement [Abstract]
Revenue
General and administrative expense	2,881	1,914	5,566	3,607
Research and development expense	2,133	1,405	4,702	2,856
Total operating expenses	5,014	3,319	10,268	6,463
Loss from operations	(5,014)	(3,319)	(10,268)	(6,463)
Other income (expense)
Interest expense			(52)
Change in fair value - Senior Secured Convertible Notes and Senior Convertible Note	2,120	(161)	(5,888)	(720)
Offering costs - Senior Secured Convertible Note and Senior Convertible Note	(200)		(610)
Debt extinguishments loss - Senior Secured Convertible Notes	(2,750)	(259)	(3,937)	(260)
Other income (expense), net	(830)	(420)	(10,487)	(980)
Loss before provision for income tax	(5,844)	(3,739)	(20,755)	(7,443)
Provision for income taxes
Net loss - before noncontrolling interest	(5,844)	(3,739)	(20,755)	(7,443)
Net loss attributable to noncontrolling interest	266	145	702	314
Net loss - attributable to PAVmed Inc.	(5,578)	(3,594)	(20,053)	(7,129)
Less: Series B Convertible Preferred Stock dividends earned	(71)	(66)	(141)	(132)
Net loss attributable to PAVmed Inc. common stockholders	$ (5,649)	$ (3,660)	$ (20,194)	$ (7,261)
Net loss per share - attributable to PAVmed Inc. - basic and diluted	$ (0.12)	$ (0.13)	$ (0.45)	$ (0.26)
Net loss per share - attributable to PAVmed Inc. common stockholders - basic and diluted	$ (0.13)	$ (0.13)	$ (0.46)	$ (0.27)
Weighted average common shares outstanding - basic and diluted	44,781	27,606	44,140	27,344

Condensed Consolidated Statem_2

Condensed Consolidated Statement of Changes in Equity (Deficit) (Unaudited) - USD ($) shares in Thousands, $ in Thousands	Series B Convertible Preferred Stock [Member]	Common Stock [Member]	Additional Paid-In Capital [Member]	Accumulated Deficit [Member]	Non-controlling Interest [Member]	Total
Balance at Dec. 31, 2018	$ 2,032	$ 27	$ 32,619	$ (36,993)	$ (161)	$ (2,476)
Balance, shares at Dec. 31, 2018	1,070	27,143
Issue common stock - registered offerings, net		$ 5	5,374			5,379
Issue common stock - registered offerings, net, shares		5,480
Issue common stock upon partial conversions of Senior Secured Convertible Note		$ 2	1,812			1,814
Issue common stock upon partial conversions of Senior Secured Convertible Note, shares		1,516
Series B Convertible Preferred Stock dividends declared	$ 130			(130)
Series B Convertible Preferred Stock dividends declared, shares	43
Stock-based compensation			706			706
Stock-based compensation - majority-owned subsidiary			8		133	141
Loss				(7,129)	(315)	(7,443)
Balance at Jun. 30, 2019	$ 2,162	$ 34	40,519	(44,251)	(343)	(1,879)
Balance, shares at Jun. 30, 2019	1,113	34,139
Balance at Dec. 31, 2018	$ 2,032	$ 27	32,619	(36,993)	(161)	(2,476)
Balance, shares at Dec. 31, 2018	1,070	27,143
Balance at Dec. 31, 2019	$ 2,296	$ 41	47,554	(53,715)	(814)	(4,638)
Balance, shares at Dec. 31, 2019	1,158	40,479
Balance at Mar. 31, 2019	$ 2,096	$ 28	33,025	(40,591)	(226)	(5,668)
Balance, shares at Mar. 31, 2019	1,091	27,193
Issue common stock - registered offerings, net		$ 5	5,374			5,379
Issue common stock - registered offerings, net, shares		5,480
Issue common stock upon partial conversions of Senior Secured Convertible Note		$ 1	1,760			1,761
Issue common stock upon partial conversions of Senior Secured Convertible Note, shares		1,466
Series B Convertible Preferred Stock dividends declared	$ 66			(66)
Series B Convertible Preferred Stock dividends declared, shares	22
Stock-based compensation			356			356
Stock-based compensation - majority-owned subsidiary			4		28	32
Loss				(3,594)	(145)	(3,739)
Balance at Jun. 30, 2019	$ 2,162	$ 34	40,519	(44,251)	(343)	(1,879)
Balance, shares at Jun. 30, 2019	1,113	34,139
Balance at Dec. 31, 2019	$ 2,296	$ 41	47,554	(53,715)	(814)	(4,638)
Balance, shares at Dec. 31, 2019	1,158	40,479
Issue common stock upon partial conversions of Senior Secured Convertible Note		$ 6	11,567			11,573
Issue common stock upon partial conversions of Senior Secured Convertible Note, shares		5,828
Series B Convertible Preferred Stock dividends declared	$ 140			(140)
Series B Convertible Preferred Stock dividends declared, shares	47
Stock-based compensation			840			840
Stock-based compensation - majority-owned subsidiary			6		26	32
Issue common stock - Employee Stock Purchase Plan			126			126
Issue common stock - Employee Stock Purchase Plan, shares		154
Issue common stock - exercise Series S warrants		$ 1	11			12
Issue common stock - exercise Series S warrants, shares		1,199
Issue common stock - conversion Series B Convertible Preferred Stock	$ (43)		43
Issue common stock - conversion Series B Convertible Preferred Stock, shares	(25)	25
Vesting of restricted stock awards
Vesting of restricted stock awards, shares		234
Issue common stock of majority-owned subsidiary exercise of stock options					5	5
Loss				(20,053)	(702)	(20,755)
Balance at Jun. 30, 2020	$ 2,393	$ 48	60,147	(73,908)	(1,485)	(12,805)
Balance, shares at Jun. 30, 2020	1,180	47,919
Balance at Mar. 31, 2020	$ 2,322	$ 44	50,896	(68,259)	(1,232)	(16,229)
Balance, shares at Mar. 31, 2020	1,156	44,134
Issue common stock upon partial conversions of Senior Secured Convertible Note		$ 4	8,735			8,739
Issue common stock upon partial conversions of Senior Secured Convertible Note, shares		3,785
Series B Convertible Preferred Stock dividends declared	$ 71			(71)
Series B Convertible Preferred Stock dividends declared, shares	24
Stock-based compensation			513			513
Stock-based compensation - majority-owned subsidiary			3		13	16
Loss				(5,578)	(266)	(5,844)
Balance at Jun. 30, 2020	$ 2,393	$ 48	$ 60,147	$ (73,908)	$ (1,485)	$ (12,805)
Balance, shares at Jun. 30, 2020	1,180	47,919

Condensed Consolidated Statem_3

Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2020	Jun. 30, 2019
Cash flows from operating activities
Net loss - before noncontrolling interest ('NCI")	$ (20,755)	$ (7,443)
Adjustments to reconcile net loss - before NCI to net cash used in operating activities
Depreciation expense	9	7
Stock-based compensation	872	847
Change in fair value - Senior Secured Convertible Notes and Senior Convertible Note	5,888	720
Debt extinguishment loss - Senior Secured Convertible Notes	3,937	260
Changes in operating assets and liabilities:
Prepaid expenses and other current assets	(747)	140
Accounts payable	1,294	(312)
Accrued expenses and other current liabilities	155	(608)
Net cash flows used in operating activities	(9,346)	(6,389)
Cash flows from investing activities
Purchase of equipment	(44)	(25)
Net cash flows used in investing activities	(44)	(25)
Cash flows from financing activities
Proceeds - issue of Senior Secured Convertible Notes	6,300
Proceeds - issue of Senior Convertible Note	3,700
Proceeds - Cares Act Paycheck Protection Program Loan	300
Proceeds - issue of common stock - registered offerings		5,480
Payment - offering costs - registered offerings		(101)
Payment - Senior Secured Convertible Notes - non-installment	(192)	(279)
Proceeds - issue common stock - Employee Stock Purchase Plan	126
Proceeds - exercise of Series S Warrants	12
Proceeds - exercise of stock options issued under equity incentive plan of majority owned subsidiary	5
Net cash flows provided by financing activities	10,251	5,100
Net increase (decrease) in cash	861	(1,314)
Cash, beginning of period	6,219	8,222
Cash, end of period	$ 7,080	$ 6,908

The Company and Description of

The Company and Description of the Business	6 Months Ended
	Jun. 30, 2020
Organization, Consolidation and Presentation of Financial Statements [Abstract]
The Company and Description of the Business	Note 1 — The Company and Description of the Business PAVmed Inc. (“PAVmed” or the “Company”) together with its majority owned subsidiaries, Lucid Diagnostics, Inc (“Lucid Diagnostics” or “LUCID”) and Solys Diagnostics, Inc. (“Solys Diagnostics” or “SOLYS”) were organized to advance a broad pipeline of innovative medical technologies from concept to commercialization, employing a business model focused on capital efficiency and speed to market. The Company’s activities have focused on advancing the lead products towards regulatory approval and commercialization, protecting its intellectual property, and building its corporate infrastructure and management team. The Company operates in one segment as a medical device company. The ability of the Company to generate revenue depends upon the Company’s ability to successfully advance the commercialization of EsoGuard and CarpX while also completing the development and the necessary regulatory approvals of its other products and services. In this regard: ● EsoCheck has received 510(k) marketing clearance from the FDA as an esophageal cell collection device in June 2019; ● EsoGuard completed the certification required by the Clinical Laboratory Improvement Amendment (“CLIA”) and accreditation of the College of American Pathologists (“CAP”) making it commercially available as a Laboratory Developed Test (“LDT”) at LUCID’s contract diagnostic laboratory service provider in California in December 2019; and, ● CarpX, developed as a patented, single-use, disposable, minimally invasive device designed as a precision cutting tool to treat carpal tunnel syndrome while reducing recovery times, received 510(k) marketing clearance from the FDA in April 2020. Although the Company’s current operational activities are principally focused on the commercialization of EsoGuard and CarpX its development activities are focused on pursuing FDA approval and clearance of other lead products in our product portfolio pipeline, including EsoGuard IVD, PortIO, DisappEAR, NextFlo, and EsoCure. The Company has financed its operations principally through the public and private issuances of its common stock, preferred stock, warrants, and debt. All amounts in these accompanying notes to unaudited condensed consolidated financial statements are presented in thousands, if not otherwise noted as being presented in millions, except for per share amounts.

Financial Condition, Going Conc

Financial Condition, Going Concern and Management Plans	6 Months Ended
	Jun. 30, 2020
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Financial Condition, Going Concern and Management Plans	Note 2 — Financial Condition, Going Concern and Management Plans The Company is subject to all of the risks and uncertainties typically faced by diagnostic and medical device companies that devote substantially all of their efforts to the commercialization of their initial product and services and ongoing R&D and clinical trials. The Company expects to continue incurring losses for the foreseeable future. The Company’s existing liquidity is not sufficient to fund its operations, anticipated capital expenditures and working capital funding until the Company reaches significant revenues. As such, the Company intends to rely on capital markets to obtain additional equity or debt financing, especially if the Company experiences downturns in its business that are more severe or longer than anticipated, or if the Company experiences significant increases in expense levels resulting from being a publicly-traded company or from expansion of operations. If the Company attempts to obtain additional equity or debt financing, the Company cannot assume that such financing will be available to the Company on favorable terms, or at all. As a result of recurring operating losses and net operating cash flow deficits there is substantial doubt about the Company’s ability to continue as a going concern within one year from the date of this filing. The unaudited condensed consolidated financial statements have been prepared assuming that the Company will continue as a going concern, and do not include any adjustments to reflect the possible future effects on the recoverability and classification of assets, or the amounts and classification of liabilities that may result from the outcome of this uncertainty.

Summary of Significant Accounti

Summary of Significant Accounting Policies	6 Months Ended
	Jun. 30, 2020
Accounting Policies [Abstract]
Summary of Significant Accounting Policies	Note 3 — Summary of Significant Accounting Policies Significant Accounting Policies Other than as described below, there have been no material changes in the Company’s significant accounting policies to those previously disclosed in the Company’s annual report on Form 10-K, which was filed with the SEC on April 14, 2020. Basis of Presentation The accompanying unaudited condensed consolidated financial statements include the accounts of the Company and its wholly-owned and majority-owned subsidiaries. All intercompany transactions and balances have been eliminated in consolidation. The Company holds a majority ownership interest and has controlling financial interest in Lucid Diagnostics Inc. and Solys Diagnostics Inc., with the corresponding noncontrolling interest included as a separate component of consolidated stockholders’ equity, including the recognition in the consolidated statement of the net loss attributable to the noncontrolling interest based on the respective minority ownership interest of each respective entity. The condensed consolidated balance sheet as of December 31, 2019, which has been derived from audited consolidated financial statements, and the unaudited condensed consolidated financial statements, have been prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”), and applicable rules and regulations of the United States Securities and Exchange Commission (“SEC”) regarding interim financial reporting. As permitted under SEC rules, certain footnotes or other financial information normally required by U.S. GAAP have been condensed or omitted, and accordingly the balance sheet as of December 31, 2019 has been derived from audited consolidated financial statements at such date but does not include all of the information required by U.S. GAAP for complete consolidated financial statements. These unaudited condensed consolidated financial statements have been prepared on the same basis as the Company’s annual consolidated financial statements, and in the opinion of management, include all adjustments, consisting only of normal recurring adjustments, necessary for a fair presentation of the Company’s consolidated financial information. The results of operations for the three and six months ended June 30, 2020 are not necessarily indicative of the results to be expected for the year ending December 31, 2020 or for any other interim period or for any other future periods. The accompanying unaudited condensed consolidated financial statements and related consolidated financial information should be read in conjunction with the audited consolidated financial statements and related notes thereto as of and for the year ended December 31, 2019 included in the Company’s Annual Report on Form 10-K filed with the SEC on April 14, 2020. Use of Estimates In preparing unaudited condensed consolidated financial statements in conformity with U.S. GAAP, management is required to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements, as well as the reported amounts of expenses during the reporting period. Due to inherent uncertainty involved in making estimates, actual results reported in future periods may be affected by changes in these estimates. On an ongoing basis, the Company evaluates its estimates and assumptions. These estimates and assumptions include valuing equity securities in share-based payment arrangements and estimating the fair value of financial instruments recorded as liabilities. In addition, management’s assessment of the Company’s ability to continue as a going concern involves the estimation of the amount and timing of future cash inflows and outflows. Recent Accounting Standards Adoption of new accounting Standard On January 1, 2020, the Company adopted Financial Accounting Standards Board (“FASB”) Accounting Standard Update (“ASU”) 2018-07, Improvements to Nonemployee Share-Based Payment Accounting, On January 1, 2020, the Company adopted ASU 2018-13, Fair Value Measurement (Topic 820): Disclosure Framework—Changes to the Disclosure Requirements for Fair Value Measurement, In November 2018, the FASB issued ASU No. 2018-18, “Collaborative Arrangements (Topic 808): Clarifying the Interaction Between Topic 808 and Topic 606” In August 2020, the FASB issued its Accounting Standards Update (“ASU”) 2020-06, Debt – Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging – Contracts in Entity’s Own Equity (Subtopic 815 – 40)

Prepaid Expenses and Other Curr

Prepaid Expenses and Other Current Assets	6 Months Ended
	Jun. 30, 2020
Prepaid Expense and Other Assets, Current [Abstract]
Prepaid Expenses and Other Current Assets	Note 4 — Prepaid Expenses and Other Current Assets Prepaid expenses and other current assets consisted of the following as of: June 30, 2020 December 31, 2019 Advanced payments to service providers and suppliers $ 465 $ 294 EsoCheck cell collection supplies 375 — Deposits 234 34 Total prepaid expenses and other current assets $ 1,074 $ 328

Accrued Expenses and Other Curr

Accrued Expenses and Other Current Liabilities	6 Months Ended
	Jun. 30, 2020
Accrued Liabilities [Abstract]
Accrued Expenses and Other Current Liabilities	Note 5 — Accrued Expenses and Other Current Liabilities Accrued expenses and other current liabilities consisted of the following as of: June 30, 2020 December 31, 2019 Compensation related expenses $ 1,088 $ 1,075 EsoGuard License Agreement fee 223 223 Operating Expenses 230 88 Total accrued expenses and other current liabilities $ 1,541 $ 1,386

Related Party Transactions

Related Party Transactions	6 Months Ended
	Jun. 30, 2020
Related Party Transactions [Abstract]
Related Party Transactions	Note 6 — Related Party Transactions During the three and six months ended June 30, 2020 and 2019 the Company incurred the following expenses with the minority shareholders of Lucid Diagnostics Inc.: For the three months ended June 30, For the six months ended June 30, 2020 2019 2020 2019 CWRU patent related fees $ 27 $ 47 $ 59 $ 78 Clinical supplies – EsoCheck — — 15 — EsoGuard Physician Inventors’ consulting agreements 15 36 53 74 Stock based compensation expense 6 24 12 48 Total $ 48 $ 107 $ 139 $ 200

Commitment and Contingencies

Commitment and Contingencies	6 Months Ended
	Jun. 30, 2020
Commitments and Contingencies Disclosure [Abstract]
Commitment and Contingencies	Note 7 — Commitment and Contingencies Office Leases Total rent expense incurred under office rental agreements was $49 and $33, for the three months ended June 30, 2020 and 2019, respectively, and $98 and $65, for the six months ended June 30, 2020 and 2019, respectively. As of June 30, 2020, the Company’s future minimum lease payments for such office rental agreements are estimated to be a total of approximately $135 for the period July 1, 2020 to June 30, 2021.

Stock-Based Compensation

Stock-Based Compensation	6 Months Ended
	Jun. 30, 2020
Share-based Payment Arrangement [Abstract]
Stock-Based Compensation	Note 8 — Stock-Based Compensation PAVmed Inc. 2014 Long-Term Incentive Equity Plan - Stock Options Stock options issued and outstanding under the PAVmed Inc 2014 Long-Term Incentive Equity Plan (PAVmed Inc. 2014 Equity Plan”) for the period noted is as follows: Number Weighted Remaining Outstanding stock options at December 31, 2019 5,204 $ 2.68 8.1 Granted 1,345 $ 2.18 9.8 Exercised — $ — Forfeited — $ — Outstanding stock options at June 30, 2020 6,549 $ 2.58 7.7 Vested and exercisable stock options at June 30, 2020 4,016 $ 3.13 7.3 The aggregate intrinsic value of stock options granted under the PAVmed Inc. 2014 Equity as of June 30, 2020 was $2,468 with respect to stock options outstanding and $1,263 with respect to such stock options vested and exercisable. The intrinsic value is computed as the difference between the quoted price of the PAVmed Inc. common stock on June 30, 2020 and the exercise price of the underlying PAVmed Inc. stock options, to the extent such quoted price is greater than the exercise price. In the six months ended June 30, 2020, a total of 1,345 stock options were granted under the PAVmed Inc. 2014 Equity Plan, with each such stock option grant having a ten year contractual term from date-of-grant, vesting ratably over twelve quarters commencing with the grant date quarter, with a weighted average exercise price of $2.18 per share of common stock of PAVmed Inc. Subsequent to June 30, 2020, in July 2020, the Company issued 100 common stock options, with each such stock option grant having a ten year contractual term from date-of-grant, vesting ratably over twelve quarters commencing with the grant date quarter, with a weighted average exercise price of $2.04 per share of common stock of PAVmed Inc. PAVmed Inc 2014 Long-Term Incentive Equity Plan - Restricted Stock Awards On March 15, 2019, a total of 700 restricted stock awards were granted to employees under the PAVmed Inc. 2014 Equity Plan, with such restricted stock awards vesting ratably on an annual basis over a three year period with an initial annual vesting date of March 15, 2020. The restricted stock awards are subject to forfeiture if the requisite service period is not completed. On March 15, 2020, approximately 234 of such restricted stock awards vested. On May 1, 2020, a total of 950 restricted stock awards were granted to employees under the PAVmed Inc. 2014 Equity Plan, with such restricted stock awards vesting ratably on an annual basis over a three year period with an initial annual vesting date of May 1, 2021. The restricted stock awards are subject to forfeiture if the requisite service period is not completed. Subsequent to June 30, 2020, at the Company’s annual meeting of stockholders on July 24, 2020, the Company’s stockholders approved an increase to the share reservation of the PAVmed Inc 2014 Equity Plan of an additional 2.0 million shares of common stock of the Company, to 10.0 million shares. PAVmed Inc Employee Stock Purchase Plan (“ESPP”) The PAVmed Inc. Employee Stock Purchase Plan (“ESPP”) provides eligible employees the opportunity to purchase shares of PAVmed Inc. common stock through payroll deductions during six month periods, wherein the purchase price per share of common stock is the lower of 85% of the quoted closing price per share of PAVmed Inc. common stock at the beginning or end of each six month share purchase period. The PAVmed Inc. ESPP share purchase dates are March 31 and September 30. On the March 31, 2020 ESPP purchase date, 154 shares of PAVmed Inc. common stock were issued for proceeds of approximately $0.1 million. Subsequent to June 30, 2020, at the Company’s annual meeting of stockholders on July 24, 2020, the Company’s stockholders approved an increase to the share reservation of the PAVmed Inc ESPP of an additional 500 shares of common stock of the Company, to 750 shares. Lucid Diagnostics Inc. 2018 Long-Term Incentive Equity Plan - Stock Options The Lucid Diagnostics Inc. 2018 Long-Term Incentive Equity Plan (“Lucid Diagnostics Inc. 2018 Equity Plan”) is separate and apart from the PAVmed Inc. 2014 Equity Plan discussed above. Stock options issued and outstanding under the Lucid Diagnostics Inc. 2018 Equity Plan for the period noted is as follows: Number Weighted Remaining Outstanding stock options at December 31, 2019 995 $ 0.86 9.0 Granted — $ — Exercised 3 $ 1.50 Forfeited — $ — Outstanding stock options at June 30, 2020 992 $ 0.86 8.5 Vested and exercisable stock options at June 30, 2020 574 $ 0.83 8.4 Stock options granted under the Lucid Diagnostics Inc. 2018 Equity Plan, have a ten year contractual term from date of grant, and vest ratably over twelve successive calendar quarters, with first vesting date in the quarter of the date of grant. During the six months ended June 30, 2020, 3 stock options issued under the Lucid Diagnostics Inc. 2018 Equity Plan were exercised for cash proceeds of $5, resulting in the issue of a corresponding number of shares of common stock of Lucid Diagnostics Inc. Stock-Based Compensation Expense Consolidated stock-based compensation expense recognized for both the PAVmed Inc. 2014 Equity Plan and the Lucid Diagnostics Inc. 2018 Equity Plan, with respect to stock options and restricted stock awards as discussed above, for the periods indicated, was as follows: Three Months Ended Six Months Ended June 30, June 30, 2020 2019 2020 2019 General and administrative expenses $ 407 $ 299 $ 684 $ 584 Research and development expenses 122 89 188 263 Total $ 529 $ 388 $ 872 $ 847 As of June 30, 2020, unrecognized stock-based compensation expense and weighted average remaining requisite service period with respect to stock options and restricted stock awards issued under each of the PAVmed Inc. 2014 Equity Plan and the Lucid Diagnostics Inc 2018 Equity Plan, as discussed above, is as follows: Unrecognized Expense Weighted Average PAVmed Inc. 2014 Equity Plan Stock Options $ 2,269 1.2 years Restricted Stock Awards $ 2,243 2.6 years Lucid Diagnostics Inc. 2018 Equity Plan Stock Options $ 75 1.3 years Stock-based compensation expense recognized with respect to stock options granted under the PAVmed Inc. 2014 Equity Plan was based on a weighted average estimated fair value of such stock options of $0.92 per share and $0.93 per share during the six months ended June 30, 2020 and 2019, respectively, calculated using the following weighted average Black-Scholes valuation model assumptions: Six Months Ended June 30, 2020 2019 Expected term of stock options (in years) 5.7 5.7 Expected stock price volatility 56 % 50 % Risk free interest rate 2.0 % 2.3 % Expected dividend yield 0 % 0 % Stock-based compensation expense recognized with respect to stock options granted under the PAVmed Inc. 2014 Equity Plan to non-employees under the previous provisions FASB ASC 505-50 in the prior year six months ended June 30, 2019, was based on a weighted average estimated fair value of such stock options of $1.90 per share, calculated using Black-Scholes valuation model weighted-average assumptions of 8.7 year contractual term, a 60% expected stock price volatility, a 2.3% risk free interest rate, and a 0% expected dividend rate. The restricted stock awards granted to employees under the PAVmed Inc. 2014 Equity Plan are measured at their grant date estimated fair value based on the date-of-grant quoted price per share of PAVmed Inc. common stock. The 700 restricted stock awards granted on March 15, 2019 had an aggregate fair value of approximately $742 with such stock-based compensation expense recognized ratably over the requisite service period, which is the three year vesting period as discussed above. The 950 restricted stock awards granted on May 1, 2020 had an aggregate fair value of approximately $1,938 with such stock-based compensation expense recognized ratably over the requisite service period, which is the three year vesting period as discussed above. The stock-based compensation expense recognized with respect to these restricted stock awards was approximately $144 and $62 in the three months ended June 30, 2020 and 2019, respectively, and $206 and $82 in the six months ended June 30, 2020 and 2019, respectively, classified in general and administrative expenses; and $25 in the three and six months ended June 30, 2020 classified in research and development expenses, as presented above. Stock-based compensation expense recognized with respect to stock options granted under the Lucid Diagnostics Inc. 2018 Equity Plan was based on a weighted average estimated fair value of such stock options of $0.30 per share and $0.39 per share during the six months ended June 30, 2020 and 2019, respectively, and was calculated using the following weighted average Black-Scholes valuation model assumptions: Six Months Ended June 30, 2020 2019 Expected term of stock options (in years) 5.2 5.7 Expected stock price volatility 60 % 63 % Risk free interest rate 1.9 % 2.5 % Expected dividend yield 0 % 0 % Stock-based compensation expense recognized with respect to stock options granted under the Lucid Diagnostics Inc. 2018 Equity Plan to non-employees under the previous provisions FASB ASC 505-50 in the prior year three and six months ended June 30, 2019, was based on a weighted average estimated fair value of such stock options of $0.61 per share, calculated using Black-Scholes valuation model weighted-average assumptions of 9.1 year contractual term, a 62% expected stock price volatility, a 2.2% risk free interest rate, and a 0% expected dividend rate. The Company uses the Black-Scholes valuation model to estimate the fair value of stock options granted under both the PAVmed Inc. 2014 Equity Plan and the Lucid Diagnostics Inc. 2018 Equity Plan, which requires the Company to make certain estimates and assumptions, with the weighted-average valuation assumptions for stock-based awards, principally as follows: ● The expected term of stock options represents the period of time stock options are expected to be outstanding, which is the expected term derived using the simplified method and, through December 31, 2019 for non-employees (under the previous provisions FASB ASC 505-50), was the remaining contractual term; ● With respect to stock options granted under the PAVmed Inc. 2014 Equity Plan, the expected stock price volatility is based on the historical stock price volatility of PAVmed Inc. common stock (“PAVM”) and the volatilities of similar entities within the medical device industry over the period commensurate with the expected term, and through December 31, 2019 for non-employees (under the previous provisions FASB ASC 505-50), was the remaining contractual term of the respective stock option; and, with respect to stock options granted under the Lucid Diagnostics Inc. 2018 Equity Plan, the expected stock price volatility is based on the historical stock price volatilities of similar entities within the medical device industry over the period commensurate with the expected term, and through December 31, 2019 for non-employees (under the previous provisions FASB ASC 505-50), was the remaining contractual term of the respective stock option; ● The risk-free interest rate is based on the interest rate payable on U.S. Treasury securities in effect at the time of grant for a period commensurate with the expected term of the stock option; and, ● The expected dividend yield is based on annual dividends of $0.00 as there has not been a dividend paid to-date, and there is no plan to pay dividends for the foreseeable future. The price per share of PAVmed Inc. common stock used in the computation of estimated fair value of stock options granted under the PAVmed Inc. 2014 Equity Plan is its quoted closing price per share. The price per share of Lucid Diagnostics Inc. common stock used in the computation of estimated fair value of stock options granted under the Lucid Diagnostics Inc. 2018 Equity Plan was estimated using a discounted cash flow method applied to a multi-year forecast of its future cash flows.

Financial Instruments Fair Valu

Financial Instruments Fair Value Measurements	6 Months Ended
	Jun. 30, 2020
Fair Value Disclosures [Abstract]
Financial Instruments Fair Value Measurements	Note 9 — Financial Instruments Fair Value Measurements Recurring Fair Value Measurements The fair value hierarchy table for the periods indicated is as follows: Fair Value Measurement on a Recurring Basis at Reporting Date Using (1) Level-1 Level-2 Level-3 Inputs Inputs Inputs Total June 30, 2020 Senior Secured Convertible Note - November 2019 $ 12,300 $ 12,300 Senior Secured Convertible Note - April 2020 $ — $ — $ 3,900 $ 3,900 Totals $ — $ — $ 16,200 $ 16,200 December 31, 2019 Senior Secured Convertible Note - December 2018 $ 1,700 $ 1,700 Senior Secured Convertible Note - November 2019 $ — $ — $ 6,439 $ 6,439 Totals $ — $ — $ 8,139 $ 8,139 (1) As noted above, as presented in the fair value hierarchy table, Level-1 represents quoted prices in active markets for identical items, Level-2 represents significant other observable inputs, and Level-3 represents significant unobservable inputs. There were no transfers between the respective Levels during the six-month period ended June 30, 2020. The April 2020 Senior Convertible Note, the November 2019 Senior Secured Convertible Notes and the December 2018 Senior Secured Convertible Note are each accounted for under the ASC 825-10-15-4 fair value option (“FVO”) election. Under the FVO election the financial instrument is initially measured at its issue-date estimated fair value and subsequently remeasured at estimated fair value on a recurring basis at each reporting period date. As provided for by ASC 825-10-50-30(b), the estimated fair value adjustment is presented as a single line item within other income (expense) in the accompanying unaudited condensed consolidated statement of operations. The following table presents changes in Level 3 liabilities measured at fair value for the six-month period ended June 30, 2020 and 2019. Both observable and unobservable inputs were used to determine the fair value of positions that the Company has classified within the Level 3 category. Unrealized gains and losses associated with liabilities within the Level 3 category include changes in fair value attributable to both observable (e.g., changes in market interest rates) and unobservable (e.g., changes in unobservable long- dated volatilities) inputs: Fair Value Assumptions – June 30, 2020: November 2019 Senior Secured Convertible Note Series A & Series B April 2020 Senior Convertible Note Required rate of return 29 % 68 % Conversion Price $ 1.60 $ 5.00 Expected term (years) 1.25 1.83 Volatility 79 % 65 % Risk free rate 0.16 % 0.16 % Dividend yield 0 % 0 % Fair Value Assumptions – June 30, 2019: Required rate of return 11.1 % Conversion Price $ 1.60 Expected term (years) 1.51 Volatility 53 % Risk free rate 1.8 % Dividend yield 0 %

Outstanding Debt

Outstanding Debt	6 Months Ended
	Jun. 30, 2020
Debt Disclosure [Abstract]
Outstanding Debt	Note 10 — Outstanding Debt The fair value and face value principal of outstanding debt as of the dates indicated is as follows: Contractual Stated Interest Rate Conversion Price Face Value Fair Value December 2018 Senior Secured Convertible Note (1) December 31, 2020 7.875 % $ 1.60 $ — $ — November 2019 Senior Secured Convertible Note (2) (3) September 30, 2021 7.875 % $ 1.60 $ 8,305 $ 12,300 April 2020 Senior Convertible Note (4) April 30, 2022 7.875 % $ 5.00 4,111 3,900 Balance as of June 30, 2020 $ 12,416 $ 16,200 December 2018 Senior Secured Convertible Note (1) December 31, 2020 7.875 % $ 1.60 $ 1,692 $ 1,700 November 2019 Senior Secured Convertible Note (2) September 30, 2021 7.875 % $ 1.60 7,000 $ 6,439 Balance as of December 31, 2019 $ 8,692 $ 8,139 The changes in the fair value of debt during the three and six months ended June 30, 2020 is as follows: December 2018 Senior Secured November 2019 April 2020 Senior Convertible Note Sum of Balance Sheet Other Income (Expense) Fair Value - December 31, 2019 $ 1,700 $ 6,439 $ — $ 8,139 Face value principal – issue date — 7,000 — 7,000 Fair value adjustment – issue date — 2,600 — 2,600 (2,600 ) Installment repayments – common stock (1,642 ) — — (1,642 ) Non-installment payments – common stock (4 ) — — (4 ) Non-installment payments – cash — (138 ) — (138 ) Change in fair value 9 4,699 — 4,708 (4,708 ) Lender Fee - November 2019 Senior Secured Convertible Note - Series B — — — — (700 ) Fair Value at March 31, 2020 $ 63 $ 20,600 $ — $ 20,663 Other Income (Expense) - Change in fair value - three months ended March 31, 2020 $ (8,008 ) Face value principal – issue date — — 4,111 4,111 Fair value adjustment – issue date — — (411 ) (411 ) 411 Installment repayments – common stock (50 ) (5,695 ) — (5,745 ) Non-installment payments – common stock (2 ) (242 ) — (244 ) Non-installment payments – cash — — (54 ) (54 ) Change in fair value (11 ) (2,363 ) 254 (2,120 ) 2,120 Lender Fee - April 2020 Senior Convertible Note — — — — (411 ) Fair Value at June 30, 2020 $ — $ 12,300 $ 3,900 $ 16,200 Other Income (Expense) - Change in fair value - three months ended June 30, 2020 $ 2,120 Other Income (Expense) - Change in fair value - six months ended June 30, 2020 $ (5,888 ) The changes in the fair value of debt during the three six months ended June 30, 2019 is as follows: December 2018 Senior Secured Convertible Note Other Income (Expense) Fair Value - December 31, 2018 $ 7,903 $ Installment repayments - common stock (52 ) Non-installment payments - common stock Non-installment payments - cash (159 ) Change in fair value 559 (559 ) Fair Value - March 31, 2019 8,251 Other Income (Expense) - Change in fair value (559 ) Installment repayments - common stock (1,480 ) Non-installment payments - common stock (22 ) Non-installment payments - cash (120 ) Change in fair value 161 (161 ) Fair Value - June 30, 2019 $ 6,790 Other Income (Expense) - Change in fair value (161 ) Other Income (Expense) - Change in fair value $ (720 ) (1) With respect to the December 2018 Senior Secured Convertible Note, in the six months ended June 30, 2020, approximately $1,692 of principal repayments and approximately $6 of non-installment payments were settled through the issuance of approximately 2,075 shares of common stock of the Company with a fair value of approximately $2,901 (with such fair value measured as the respective conversion date quoted closing price of the common stock of the Company). As of June 30, 2020, the December 2018 Senior Secured Debt balance was paid in full. (2) With respect to the November 2019 Senior Secured Convertible Note - Series A and Series B - in the six months ended June 30, 2020, approximately $5,695 of Accelerated and Bi-Monthly Installment principal repayments and approximately $242 of non-installment payments were settled through the issuance of approximately 3,753 shares of common stock of the Company with a fair value of approximately $8,671 (with such fair value measured as the respective conversion date quoted closing price of the common stock of the Company). Additionally, non-installment payments of approximately $138 were paid in cash in the same period. There were no such installment repayments nor non-installment payments in the corresponding prior year period. Subsequent to June 30, 2020, through August 11, 2020, approximately $480 of Accelerated and Bi-Monthly Installment principal repayments and approximately $4 of non-installment payments were settled through the issuance of approximately 303 shares of common stock of the Company with a fair value of approximately $618 (with such fair value measured as the respective conversion date quoted closing price of the common stock of the Company). (3) The November 2019 Senior Secured Convertible Note - Series B has a face value principal of approximately $7,000 and lender fees of approximately $700 (recognized as a current period other expense), resulting in cash proceeds of approximately $6,300 received by the Company, with such cash proceeds delivered to the Company by the investors on March 30, 2020, at their election under the prepayment provisions of the Series B note of the November 2019 Senior Secured Convertible Note. Additionally, under a separate agreement, the Company incurred an expense of approximately $410 with respect to the placement agent advisory fee. The November 2019 Senior Secured Convertible Note - Series B has a contractual maturity date of September 30, 2021 and a stated interest rate of 7.875% per annum. The November 2019 Senior Secured Convertible Notes - Series A and Series B - have a stated interest rate of 7.875% per annum to the extent the investor has funded the cash proceeds of each such respective Series A and Series B. During the period November 4, 2019 to March 29, 2020, during which period the Series B was not funded by the investor, the Company incurred interest expense of 3.0% per annum on the Series B $7.0 million face value principal. The (cash) payment of such 3.0% interest on the $7.0 million face value principal resulted in the recognition of approximately $53 of interest expense during the period January 1, 2020 through March 29, 2020, with such interest expense included in other income (expense) in the accompanying (unaudited) condensed consolidated statement of operations. There was no such interest expense in the corresponding prior year period. (4) On April 30, 2020, the Company entered into a Security Purchase Agreement for the issue of a Senior Convertible Note with a face value principal of approximately $4,111 and lender fees of approximately $411 (recognized as a current period other expense), resulting in $3,700 cash proceeds received by the Company. - referred to as the April 2020 Senior Convertible Note. Additionally, under a separate agreement, the Company incurred a current period expense of approximately $120 with respect to the placement agent advisory fee. The April 2020 Senior Convertible Note has a 24 month maturity, a 7.875% interest rate per annum, and a conversion price of $5.00 per share of the Company’s common stock. On the maturity date, the Company will pay the holder in cash all remaining outstanding principal and unpaid interest thereon. In the six months ended June 30, 2020 non-installment payments in cash at the stated interest rate were made in the amount of approximately $54. Subsequent to June 30, 2020, on August 5, 2020, the Company entered into a Securities Purchase Agreement (“SPA”) with an institutional investor (the “Investor”), and pursuant to the SPA, on August 6, 2020, the Company issued to the Investor a Senior Secured Convertible Note (the “August 2020 Senior Secured Convertible Note”) with a face value principal amount of $7,750 and $750 lender fee (recognized as a current period other expense), resulting in $7,000 cash proceeds received by the Company. The August 2020 Senior Secured Convertible Note has a 24 month maturity, a 7.875% interest rate per annum, and a conversion price of $5.00 per share of the Company’s common stock. On the maturity date, the Company will pay the holder in cash all remaining outstanding principal and unpaid interest thereon. The August 2020 Senior Secured Convertible Note investor and its affiliates also hold the Company’s November 2019 Senior Secured Convertible Notes the April 2020 Senior Convertible Note. The August 2020 Senior Secured Convertible Note contains certain representations and warranties, covenants and indemnities for similar transactions as well as the past transactions entered into with the investor. The August 2020 Senior Secured Convertible Note contains certain redemption rights similar to the April 2020 Senior Convertible Note and security interest with a first priority line in all of our assets, including all of the Company’ current and future significant subsidiaries, similar to the November 2019 Senior Secured Convertible Notes.

Cares Act Paycheck Protection P

Cares Act Paycheck Protection Program Loan	6 Months Ended
	Jun. 30, 2020
Commitments And Contingencies Disclosure [Table]
Cares Act Paycheck Protection Program Loan	Note 11 — Cares Act Paycheck Protection Program Loan On April 8, 2020 the Company entered into a loan agreement with JP Morgan Chase, N.A., and received approximately $300 of proceeds, pursuant to the Coronavirus Aid, Relief and Economic Security Act (the “CARES Act”) Paycheck Protection Program (“PPP”) - the “PPP Loan”. The PPP Loan matures on April 8, 2022 and bears interest at a rate of approximately 1.0% per annum. Monthly amortized principle and interest payments are deferred for six months after the PPP Loan date-of-disbursement after which time each month following the deferral period, the Company will make equal monthly payments on principal and interest balances to fully amortize the loan balances by the maturity date. As such, $150 is presented as a current liability and $150 is presented as a non-current liability in the accompanying unaudited condensed consolidated balance sheet as of June 30, 2020. The PPP Loan funds were received on April 8, 2020. The PPP Loan contains events of default and other provisions customary for a loan of this type. The Paycheck Protection Program provides that (1) the use of PPP Loan amount shall be limited to certain qualifying expenses, (2) 100 per cent of the principal amount of the loan is guaranteed by the Small Business Administration and (3) an amount up to the full principal amount may qualify for loan forgiveness in accordance with the terms of CARES Act. Under the CARES Act, loan forgiveness is available for the sum of documented payroll costs, covered rent payments, covered mortgage interest and covered utilities during either, at our discretion, the eight-week period or twenty-four week period beginning on the date of disbursement of proceeds from the PPP loan. In the event the PPP loan, or any portion thereof, is forgiven pursuant to the PPP, the amount forgiven is applied to outstanding principal. The Company is not yet able to determine the amount potentially to be forgiven, if any. As of June 30, 2020 and the date of this filing, the Company was in full compliance with the provisions of the PPP Loan.

Preferred Stock

Preferred Stock	6 Months Ended
	Jun. 30, 2020
Equity [Abstract]
Preferred Stock	Note 12 — Preferred Stock During the six months ended June 30, 2020, the Company’s board-of-directors declared the payment of Series B Convertible Preferred Stock dividends, earned as of December 31, 2019 and March 31, 2020, totaling approximately $140, which have been settled by the issue of an additional 47 shares of Series B Convertible Preferred Stock. Subsequent to June 30, 2020, in July 2020, the Company’s board-of-directors declared the payment of Series B Convertible Preferred Stock dividend payment earned as of June 30, 2020, payable as of July 1, 2020 of approximately $71 to be settled by the issue of an additional 24 shares of Series B Convertible Preferred Stock. The Series B Convertible Preferred Stock dividend payment earned as of June 30, 2020 and payable July 1, 2020, was not recognized as a dividend payable liability in the accompanying unaudited condensed consolidated balance sheet as the Company’s board of directors had not declared such dividends payable as of June 30, 2020.

Stockholders' Equity, Common St

Stockholders' Equity, Common Stock Purchase Warrants, and Noncontrolling Interest	6 Months Ended
	Jun. 30, 2020
Equity [Abstract]
Stockholders' Equity, Common Stock Purchase Warrants, and Noncontrolling Interest	Note 13 — Stockholders’ Equity, Common Stock Purchase Warrants, and Noncontrolling Interest As of June 30, 2020, a total of 17,250 common stock purchase warrants were issued and outstanding, with a weighted average exercise price of $1.68 per share of common stock of the Company; and, as of June 30, 2019, a total of 18,449 common stock purchase warrants were issued and outstanding with a weighted average exercise price of $1.57 per share of common stock of the Company. During the six months ended June 30, 2020, 1,199 Series S Warrants were exercised for cash proceeds of $12, resulting in the issuance of a corresponding number of shares of the Company’s common stock. Subsequent to June 30, 2020, at the annual meeting of stockholders held on July 24, 2020the Company’s stockholders approved an increase of authorized shares of common stock of the Company by 50.0 million shares, from 100.0 million shares to 150.0 million shares. The noncontrolling interest (“NCI”) included as a component of consolidated total stockholders’ equity for the periods indicated is as follows: Six Months Year Ended NCI - equity (deficit) - beginning of period $ (814 ) $ (162 ) Minority Interest investment in Solys Diagnostics Inc — 889 Minority Interest share subscription receivable - Solys Diagnostics Inc. — (889 ) Minority Interest Lucid Diagnostics Inc. 2018 Equity Plan stock option exercise 5 — Net loss attributable to NCI - Lucid Diagnostics Inc. (640 ) (801 ) Net loss attributable to NCI - Solys Diagnostics Inc. (62 ) (10 ) Stock-based compensation expense - Lucid Diagnostics Inc. 2018 Equity Plan 26 159 NCI - equity (deficit) - end of period $ (1,485 ) $ (814 )

Loss Per Share

Loss Per Share	6 Months Ended
	Jun. 30, 2020
Earnings Per Share [Abstract]
Loss Per Share	Note 14 —Loss Per Share Basic earnings (loss) per common share is computed by dividing net loss by the weighted average number of common shares outstanding during the reporting period. Diluted earnings (loss) per common share is computed similar to basic earnings (loss) per common share except that it reflects the potential dilution that could occur if dilutive securities or other obligations to issue common stock were exercised or converted into common stock. Diluted weighted average common shares include common stock potentially issuable under the Company’s convertible notes, preferred stock, warrants and vested and unvested stock options. The following table sets forth the computation of earnings (loss) per share attributable to PAVmed Inc. and loss per share attributable to PAVmed Inc. common stockholders for the respective periods indicated: Three Months Ended Six Months Ended June 30, June 30, 2020 2019 2020 2019 Numerator Net loss - before noncontrolling interest $ (5,844 ) $ (3,739 ) $ (20,755 ) $ (7,443 ) Net loss attributable to noncontrolling interest 266 145 702 314 Net loss - as reported, attributable to PAVmed Inc. $ (5,578 ) $ (3,594 ) $ (20,053 ) $ (7,129 ) Series B Convertible Preferred Stock dividends: $ (71 ) $ (66 ) $ (141 ) $ (132 ) Net loss attributable to PAVmed Inc. common stockholders $ (5,649 ) $ (3,660 ) $ (20,194 ) $ (7,261 ) Denominator Weighted average common shares outstanding, basic and diluted 44,781 27,606 44,140 27,344 Loss per share Basic and diluted Net loss - as reported, attributable to PAVmed Inc. $ (0.12 ) $ (0.13 ) $ (0.45 ) $ (0.26 ) Net loss attributable to PAVmed Inc. common stockholders $ (0.13 ) $ (0.13 ) $ (0.46 ) $ (0.27 ) The following common stock equivalents have been excluded from the computation of diluted weighted average shares outstanding as their inclusion would be anti-dilutive: June 30, 2020 2019 PAVmed Inc. 2014 Equity Plan stock options and restricted stock awards 7,965 5,804 Unit purchase options - as to shares of common stock 53 53 Unit purchase options - as to shares underlying Series Z Warrants 53 53 Series Z Warrants 16,815 16,815 Series W Warrants 382 382 Series B Convertible Preferred Stock 1,180 1,113 Total 26,448 24,220

Summary of Significant Accoun_2

Summary of Significant Accounting Policies (Policies)	6 Months Ended
	Jun. 30, 2020
Accounting Policies [Abstract]
Significant Accounting Policies	Significant Accounting Policies Other than as described below, there have been no material changes in the Company’s significant accounting policies to those previously disclosed in the Company’s annual report on Form 10-K, which was filed with the SEC on April 14, 2020.
Basis of Presentation	Basis of Presentation The accompanying unaudited condensed consolidated financial statements include the accounts of the Company and its wholly-owned and majority-owned subsidiaries. All intercompany transactions and balances have been eliminated in consolidation. The Company holds a majority ownership interest and has controlling financial interest in Lucid Diagnostics Inc. and Solys Diagnostics Inc., with the corresponding noncontrolling interest included as a separate component of consolidated stockholders’ equity, including the recognition in the consolidated statement of the net loss attributable to the noncontrolling interest based on the respective minority ownership interest of each respective entity. The condensed consolidated balance sheet as of December 31, 2019, which has been derived from audited consolidated financial statements, and the unaudited condensed consolidated financial statements, have been prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”), and applicable rules and regulations of the United States Securities and Exchange Commission (“SEC”) regarding interim financial reporting. As permitted under SEC rules, certain footnotes or other financial information normally required by U.S. GAAP have been condensed or omitted, and accordingly the balance sheet as of December 31, 2019 has been derived from audited consolidated financial statements at such date but does not include all of the information required by U.S. GAAP for complete consolidated financial statements. These unaudited condensed consolidated financial statements have been prepared on the same basis as the Company’s annual consolidated financial statements, and in the opinion of management, include all adjustments, consisting only of normal recurring adjustments, necessary for a fair presentation of the Company’s consolidated financial information. The results of operations for the three and six months ended June 30, 2020 are not necessarily indicative of the results to be expected for the year ending December 31, 2020 or for any other interim period or for any other future periods. The accompanying unaudited condensed consolidated financial statements and related consolidated financial information should be read in conjunction with the audited consolidated financial statements and related notes thereto as of and for the year ended December 31, 2019 included in the Company’s Annual Report on Form 10-K filed with the SEC on April 14, 2020.
Use of Estimates	Use of Estimates In preparing unaudited condensed consolidated financial statements in conformity with U.S. GAAP, management is required to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements, as well as the reported amounts of expenses during the reporting period. Due to inherent uncertainty involved in making estimates, actual results reported in future periods may be affected by changes in these estimates. On an ongoing basis, the Company evaluates its estimates and assumptions. These estimates and assumptions include valuing equity securities in share-based payment arrangements and estimating the fair value of financial instruments recorded as liabilities. In addition, management’s assessment of the Company’s ability to continue as a going concern involves the estimation of the amount and timing of future cash inflows and outflows.
Recent Accounting Standards	Recent Accounting Standards Adoption of new accounting Standard On January 1, 2020, the Company adopted Financial Accounting Standards Board (“FASB”) Accounting Standard Update (“ASU”) 2018-07, Improvements to Nonemployee Share-Based Payment Accounting, On January 1, 2020, the Company adopted ASU 2018-13, Fair Value Measurement (Topic 820): Disclosure Framework—Changes to the Disclosure Requirements for Fair Value Measurement, In November 2018, the FASB issued ASU No. 2018-18, “Collaborative Arrangements (Topic 808): Clarifying the Interaction Between Topic 808 and Topic 606” In August 2020, the FASB issued its Accounting Standards Update (“ASU”) 2020-06, Debt – Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging – Contracts in Entity’s Own Equity (Subtopic 815 – 40)

Prepaid Expenses and Other Cu_2

Prepaid Expenses and Other Current Assets (Tables)	6 Months Ended
	Jun. 30, 2020
Prepaid Expense and Other Assets, Current [Abstract]
Schedule of Prepaid Expenses and Other Current Assets	Prepaid expenses and other current assets consisted of the following as of: June 30, 2020 December 31, 2019 Advanced payments to service providers and suppliers $ 465 $ 294 EsoCheck cell collection supplies 375 — Deposits 234 34 Total prepaid expenses and other current assets $ 1,074 $ 328

Accrued Expenses and Other Cu_2

Accrued Expenses and Other Current Liabilities (Tables)	6 Months Ended
	Jun. 30, 2020
Accrued Liabilities [Abstract]
Schedule of Accrued Expenses and Other Current Liabilities	Accrued expenses and other current liabilities consisted of the following as of: June 30, 2020 December 31, 2019 Compensation related expenses $ 1,088 $ 1,075 EsoGuard License Agreement fee 223 223 Operating Expenses 230 88 Total accrued expenses and other current liabilities $ 1,541 $ 1,386

Related Party Transactions (Tab

Related Party Transactions (Tables)	6 Months Ended
	Jun. 30, 2020
Related Party Transactions [Abstract]
Schedule of Incurred Expenses of Minority Shareholders	During the three and six months ended June 30, 2020 and 2019 the Company incurred the following expenses with the minority shareholders of Lucid Diagnostics Inc.: For the three months ended June 30, For the six months ended June 30, 2020 2019 2020 2019 CWRU patent related fees $ 27 $ 47 $ 59 $ 78 Clinical supplies – EsoCheck — — 15 — EsoGuard Physician Inventors’ consulting agreements 15 36 53 74 Stock based compensation expense 6 24 12 48 Total $ 48 $ 107 $ 139 $ 200

Stock-Based Compensation (Table

Stock-Based Compensation (Tables)	6 Months Ended
	Jun. 30, 2020
Share-based Payment Arrangement [Abstract]
Schedule of Summarizes Information About Stock Options	Stock options issued and outstanding under the PAVmed Inc 2014 Long-Term Incentive Equity Plan (PAVmed Inc. 2014 Equity Plan”) for the period noted is as follows: Number Weighted Remaining Outstanding stock options at December 31, 2019 5,204 $ 2.68 8.1 Granted 1,345 $ 2.18 9.8 Exercised — $ — Forfeited — $ — Outstanding stock options at June 30, 2020 6,549 $ 2.58 7.7 Vested and exercisable stock options at June 30, 2020 4,016 $ 3.13 7.3 Stock options issued and outstanding under the Lucid Diagnostics Inc. 2018 Equity Plan for the period noted is as follows: Number Weighted Remaining Outstanding stock options at December 31, 2019 995 $ 0.86 9.0 Granted — $ — Exercised 3 $ 1.50 Forfeited — $ — Outstanding stock options at June 30, 2020 992 $ 0.86 8.5 Vested and exercisable stock options at June 30, 2020 574 $ 0.83 8.4
Schedule of Stock-Based Compensation Awards Granted	Consolidated stock-based compensation expense recognized for both the PAVmed Inc. 2014 Equity Plan and the Lucid Diagnostics Inc. 2018 Equity Plan, with respect to stock options and restricted stock awards as discussed above, for the periods indicated, was as follows: Three Months Ended Six Months Ended June 30, June 30, 2020 2019 2020 2019 General and administrative expenses $ 407 $ 299 $ 684 $ 584 Research and development expenses 122 89 188 263 Total $ 529 $ 388 $ 872 $ 847
Schedule of Unrecognized Compensation Expense	As of June 30, 2020, unrecognized stock-based compensation expense and weighted average remaining requisite service period with respect to stock options and restricted stock awards issued under each of the PAVmed Inc. 2014 Equity Plan and the Lucid Diagnostics Inc 2018 Equity Plan, as discussed above, is as follows: Unrecognized Expense Weighted Average PAVmed Inc. 2014 Equity Plan Stock Options $ 2,269 1.2 years Restricted Stock Awards $ 2,243 2.6 years Lucid Diagnostics Inc. 2018 Equity Plan Stock Options $ 75 1.3 years
Schedule of Fair Values of Stock Options Granted Using Black-scholes Valuation Model Assumptions	Stock-based compensation expense recognized with respect to stock options granted under the PAVmed Inc. 2014 Equity Plan was based on a weighted average estimated fair value of such stock options of $0.92 per share and $0.93 per share during the six months ended June 30, 2020 and 2019, respectively, calculated using the following weighted average Black-Scholes valuation model assumptions: Six Months Ended June 30, 2020 2019 Expected term of stock options (in years) 5.7 5.7 Expected stock price volatility 56 % 50 % Risk free interest rate 2.0 % 2.3 % Expected dividend yield 0 % 0 % Stock-based compensation expense recognized with respect to stock options granted under the Lucid Diagnostics Inc. 2018 Equity Plan was based on a weighted average estimated fair value of such stock options of $0.30 per share and $0.39 per share during the six months ended June 30, 2020 and 2019, respectively, and was calculated using the following weighted average Black-Scholes valuation model assumptions: Six Months Ended June 30, 2020 2019 Expected term of stock options (in years) 5.2 5.7 Expected stock price volatility 60 % 63 % Risk free interest rate 1.9 % 2.5 % Expected dividend yield 0 % 0 %

Financial Instruments Fair Va_2

Financial Instruments Fair Value Measurements (Tables)	6 Months Ended
	Jun. 30, 2020
Fair Value Disclosures [Abstract]
Schedule of Financial Liabilities Measured at Fair Value on Recurring Basis	The fair value hierarchy table for the periods indicated is as follows: Fair Value Measurement on a Recurring Basis at Reporting Date Using (1) Level-1 Level-2 Level-3 Inputs Inputs Inputs Total June 30, 2020 Senior Secured Convertible Note - November 2019 $ 12,300 $ 12,300 Senior Secured Convertible Note - April 2020 $ — $ — $ 3,900 $ 3,900 Totals $ — $ — $ 16,200 $ 16,200 December 31, 2019 Senior Secured Convertible Note - December 2018 $ 1,700 $ 1,700 Senior Secured Convertible Note - November 2019 $ — $ — $ 6,439 $ 6,439 Totals $ — $ — $ 8,139 $ 8,139 (1) As noted above, as presented in the fair value hierarchy table, Level-1 represents quoted prices in active markets for identical items, Level-2 represents significant other observable inputs, and Level-3 represents significant unobservable inputs. There were no transfers between the respective Levels during the six-month period ended June 30, 2020.
Schedule of Fair Value Assumption Used	Fair Value Assumptions – June 30, 2020: November 2019 Senior Secured Convertible Note Series A & Series B April 2020 Senior Convertible Note Required rate of return 29 % 68 % Conversion Price $ 1.60 $ 5.00 Expected term (years) 1.25 1.83 Volatility 79 % 65 % Risk free rate 0.16 % 0.16 % Dividend yield 0 % 0 % Fair Value Assumptions – June 30, 2019: Required rate of return 11.1 % Conversion Price $ 1.60 Expected term (years) 1.51 Volatility 53 % Risk free rate 1.8 % Dividend yield 0 %

Outstanding Debt (Tables)

Outstanding Debt (Tables)	6 Months Ended
	Jun. 30, 2020
Debt Disclosure [Abstract]
Summary of Outstanding Debt
Schedule of Senior Convertible Note Estimated Fair Value	The changes in the fair value of debt during the three and six months ended June 30, 2020 is as follows: December 2018 Senior Secured November 2019 April 2020 Senior Convertible Note Sum of Balance Sheet Other Income (Expense) Fair Value - December 31, 2019 $ 1,700 $ 6,439 $ — $ 8,139 Face value principal – issue date — 7,000 — 7,000 Fair value adjustment – issue date — 2,600 — 2,600 (2,600 ) Installment repayments – common stock (1,642 ) — — (1,642 ) Non-installment payments – common stock (4 ) — — (4 ) Non-installment payments – cash — (138 ) — (138 ) Change in fair value 9 4,699 — 4,708 (4,708 ) Lender Fee - November 2019 Senior Secured Convertible Note - Series B — — — — (700 ) Fair Value at March 31, 2020 $ 63 $ 20,600 $ — $ 20,663 Other Income (Expense) - Change in fair value - three months ended March 31, 2020 $ (8,008 ) Face value principal – issue date — — 4,111 4,111 Fair value adjustment – issue date — — (411 ) (411 ) 411 Installment repayments – common stock (50 ) (5,695 ) — (5,745 ) Non-installment payments – common stock (2 ) (242 ) — (244 ) Non-installment payments – cash — — (54 ) (54 ) Change in fair value (11 ) (2,363 ) 254 (2,120 ) 2,120 Lender Fee - April 2020 Senior Convertible Note — — — — (411 ) Fair Value at June 30, 2020 $ — $ 12,300 $ 3,900 $ 16,200 Other Income (Expense) - Change in fair value - three months ended June 30, 2020 $ 2,120 Other Income (Expense) - Change in fair value - six months ended June 30, 2020 $ (5,888 ) The changes in the fair value of debt during the three six months ended June 30, 2019 is as follows: December 2018 Senior Secured Convertible Note Other Income (Expense) Fair Value - December 31, 2018 $ 7,903 $ Installment repayments - common stock (52 ) Non-installment payments - common stock Non-installment payments - cash (159 ) Change in fair value 559 (559 ) Fair Value - March 31, 2019 8,251 Other Income (Expense) - Change in fair value (559 ) Installment repayments - common stock (1,480 ) Non-installment payments - common stock (22 ) Non-installment payments - cash (120 ) Change in fair value 161 (161 ) Fair Value - June 30, 2019 $ 6,790 Other Income (Expense) - Change in fair value (161 ) Other Income (Expense) - Change in fair value $ (720 ) (1) With respect to the December 2018 Senior Secured Convertible Note, in the six months ended June 30, 2020, approximately $1,692 of principal repayments and approximately $6 of non-installment payments were settled through the issuance of approximately 2,075 shares of common stock of the Company with a fair value of approximately $2,901 (with such fair value measured as the respective conversion date quoted closing price of the common stock of the Company). As of June 30, 2020, the December 2018 Senior Secured Debt balance was paid in full. (2) With respect to the November 2019 Senior Secured Convertible Note - Series A and Series B - in the six months ended June 30, 2020, approximately $5,695 of Accelerated and Bi-Monthly Installment principal repayments and approximately $242 of non-installment payments were settled through the issuance of approximately 3,753 shares of common stock of the Company with a fair value of approximately $8,671 (with such fair value measured as the respective conversion date quoted closing price of the common stock of the Company). Additionally, non-installment payments of approximately $138 were paid in cash in the same period. There were no such installment repayments nor non-installment payments in the corresponding prior year period. Subsequent to June 30, 2020, through August 11, 2020, approximately $480 of Accelerated and Bi-Monthly Installment principal repayments and approximately $4 of non-installment payments were settled through the issuance of approximately 303 shares of common stock of the Company with a fair value of approximately $618 (with such fair value measured as the respective conversion date quoted closing price of the common stock of the Company). (3) The November 2019 Senior Secured Convertible Note - Series B has a face value principal of approximately $7,000 and lender fees of approximately $700 (recognized as a current period other expense), resulting in cash proceeds of approximately $6,300 received by the Company, with such cash proceeds delivered to the Company by the investors on March 30, 2020, at their election under the prepayment provisions of the Series B note of the November 2019 Senior Secured Convertible Note. Additionally, under a separate agreement, the Company incurred an expense of approximately $410 with respect to the placement agent advisory fee. The November 2019 Senior Secured Convertible Note - Series B has a contractual maturity date of September 30, 2021 and a stated interest rate of 7.875% per annum. The November 2019 Senior Secured Convertible Notes - Series A and Series B - have a stated interest rate of 7.875% per annum to the extent the investor has funded the cash proceeds of each such respective Series A and Series B. During the period November 4, 2019 to March 29, 2020, during which period the Series B was not funded by the investor, the Company incurred interest expense of 3.0% per annum on the Series B $7.0 million face value principal. The (cash) payment of such 3.0% interest on the $7.0 million face value principal resulted in the recognition of approximately $53 of interest expense during the period January 1, 2020 through March 29, 2020, with such interest expense included in other income (expense) in the accompanying (unaudited) condensed consolidated statement of operations. There was no such interest expense in the corresponding prior year period. (4) On April 30, 2020, the Company entered into a Security Purchase Agreement for the issue of a Senior Convertible Note with a face value principal of approximately $4,111 and lender fees of approximately $411 (recognized as a current period other expense), resulting in $3,700 cash proceeds received by the Company. - referred to as the April 2020 Senior Convertible Note. Additionally, under a separate agreement, the Company incurred a current period expense of approximately $120 with respect to the placement agent advisory fee. The April 2020 Senior Convertible Note has a 24 month maturity, a 7.875% interest rate per annum, and a conversion price of $5.00 per share of the Company’s common stock. On the maturity date, the Company will pay the holder in cash all remaining outstanding principal and unpaid interest thereon. In the six months ended June 30, 2020 non-installment payments in cash at the stated interest rate were made in the amount of approximately $54.

Stockholders' Equity, Common _2

Stockholders' Equity, Common Stock Purchase Warrants, and Noncontrolling Interest (Tables)	6 Months Ended
	Jun. 30, 2020
Equity [Abstract]
Schedule of Noncontrolling Interest	The noncontrolling interest (“NCI”) included as a component of consolidated total stockholders’ equity for the periods indicated is as follows: Six Months Year Ended NCI - equity (deficit) - beginning of period $ (814 ) $ (162 ) Minority Interest investment in Solys Diagnostics Inc — 889 Minority Interest share subscription receivable - Solys Diagnostics Inc. — (889 ) Minority Interest Lucid Diagnostics Inc. 2018 Equity Plan stock option exercise 5 — Net loss attributable to NCI - Lucid Diagnostics Inc. (640 ) (801 ) Net loss attributable to NCI - Solys Diagnostics Inc. (62 ) (10 ) Stock-based compensation expense - Lucid Diagnostics Inc. 2018 Equity Plan 26 159 NCI - equity (deficit) - end of period $ (1,485 ) $ (814 )

Loss Per Share (Tables)

Loss Per Share (Tables)	6 Months Ended
	Jun. 30, 2020
Earnings Per Share [Abstract]
Schedule of Comparison of Basic and Fully Diluted Net Loss Per Share	The following table sets forth the computation of earnings (loss) per share attributable to PAVmed Inc. and loss per share attributable to PAVmed Inc. common stockholders for the respective periods indicated: Three Months Ended Six Months Ended June 30, June 30, 2020 2019 2020 2019 Numerator Net loss - before noncontrolling interest $ (5,844 ) $ (3,739 ) $ (20,755 ) $ (7,443 ) Net loss attributable to noncontrolling interest 266 145 702 314 Net loss - as reported, attributable to PAVmed Inc. $ (5,578 ) $ (3,594 ) $ (20,053 ) $ (7,129 ) Series B Convertible Preferred Stock dividends: $ (71 ) $ (66 ) $ (141 ) $ (132 ) Net loss attributable to PAVmed Inc. common stockholders $ (5,649 ) $ (3,660 ) $ (20,194 ) $ (7,261 ) Denominator Weighted average common shares outstanding, basic and diluted 44,781 27,606 44,140 27,344 Loss per share Basic and diluted Net loss - as reported, attributable to PAVmed Inc. $ (0.12 ) $ (0.13 ) $ (0.45 ) $ (0.26 ) Net loss attributable to PAVmed Inc. common stockholders $ (0.13 ) $ (0.13 ) $ (0.46 ) $ (0.27 )
Schedule of Antidilutive Securities Excluded from Computation of Diluted Earnings Per Share	The following common stock equivalents have been excluded from the computation of diluted weighted average shares outstanding as their inclusion would be anti-dilutive: June 30, 2020 2019 PAVmed Inc. 2014 Equity Plan stock options and restricted stock awards 7,965 5,804 Unit purchase options - as to shares of common stock 53 53 Unit purchase options - as to shares underlying Series Z Warrants 53 53 Series Z Warrants 16,815 16,815 Series W Warrants 382 382 Series B Convertible Preferred Stock 1,180 1,113 Total 26,448 24,220

The Company and Description o_2

The Company and Description of the Business (Details Narrative)	6 Months Ended
	Jun. 30, 2020Integer
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Number of operating segments	1

Prepaid Expenses and Other Cu_3

Prepaid Expenses and Other Current Assets - Schedule of Prepaid Expenses and Other Current Assets (Details) - USD ($) $ in Thousands	Jun. 30, 2020	Dec. 31, 2019
Prepaid Expense and Other Assets, Current [Abstract]
Advanced payments to service providers and suppliers	$ 465	$ 294
EsoCheck cell collection supplies	375
Deposits	234	34
Total prepaid expenses and other current assets	$ 1,074	$ 328

Accrued Expenses and Other Cu_3

Accrued Expenses and Other Current Liabilities - Schedule of Accrued Expenses and Other Current Liabilities (Details) - USD ($) $ in Thousands	Jun. 30, 2020	Dec. 31, 2019
Accrued Liabilities [Abstract]
Compensation related expenses	$ 1,088	$ 1,075
EsoGuard License Agreement fee	223	223
Operating Expenses	230	88
Total accrued expenses and other current liabilities	$ 1,541	$ 1,386

Related Party Transactions - Sc

Related Party Transactions - Schedule of Incurred Expenses of Minority Shareholders (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2020	Jun. 30, 2019	Jun. 30, 2020	Jun. 30, 2019
Related Party Transactions [Abstract]
CWRU patent related fees	$ 27	$ 47	$ 59	$ 78
Clinical supplies - EsoCheck			15
EsoGuard Physician Inventors' consulting agreements	15	36	53	74
Stock based compensation expense	6	24	12	48
Total	$ 48	$ 107	$ 139	$ 200

Commitments and Contingencies (

Commitments and Contingencies (Details Narrative) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2020	Jun. 30, 2019	Jun. 30, 2020	Jun. 30, 2019
Rent expense	$ 49	$ 33	$ 98	$ 65
July 1, 2020 to June 30, 2021 [Member]
Future minimum lease payments	$ 135		$ 135

Stock-Based Compensation - (Det

Stock-Based Compensation - (Details Narrative) - USD ($) $ / shares in Units, $ in Thousands	May 01, 2020	Mar. 15, 2019	Jul. 31, 2020	May 31, 2020	Jun. 30, 2020	Jun. 30, 2019	Jun. 30, 2020	Mar. 31, 2020	Jun. 30, 2019	Jul. 24, 2020	Jul. 23, 2020
Proceeds from issuance of common stock									$ 5,480
Contractual term									1 year 6 months 3 days
Expected stock price volatility									53.00%
Risk free interest rate									1.80%
Expected dividend rate									0.00%
Stock-based compensation expense					$ 529	$ 388	872		$ 847
General and Administrative Expenses [Member]
Stock-based compensation expense					407	299	684		584
Research and Development Expenses [Member]
Stock-based compensation expense					$ 122	89	$ 188		$ 263
Employee Stock Purchase Plan [Member]
Vesting portion of stock							ESPP share purchase dates are March 31 and September 30. On the March 31, 2020 ESPP purchase date, 154 shares of PAVmed Inc. common stock were issued for proceeds of approximately $0.1 million.
Number of common stock reserved					500		500
Purchase price per share percentage on ESPP plan							85.00%
Proceeds from issuance of common stock							$ 100
Subsequent Event [Member] | Common Stock [Member] | Employee Stock Purchase Plan [Member]
Number of common stock reserved										750	250
2014 Equity Plan [Member]
Aggregate Intrinsic Value					$ 2,468		2,468
Aggregate Intrinsic Value, Vested and exercisable stock options					$ 1,263		$ 1,263
Stock options granted							1,345
Stock option granted, contractual term							10 years
Stock option granted, weighted average exercise price							$ 2.18
Vesting portion of stock							2014 Equity Plan, with each such stock option grant having a ten year contractual term from date-of-grant, vesting ratably over twelve quarters commencing with the grant date quarter, with a weighted average exercise price of $2.18 per share of common stock of PAVmed Inc.
Weighted average fair value of stock options							$ 0.92		$ 0.93
Expected dividend rate							0.00%
2014 Equity Plan [Member] | Non-employees [Member]
Weighted average fair value of stock options									$ 1.90
Contractual term									8 years 8 months 12 days
Expected stock price volatility									60.00%
Risk free interest rate									2.30%
Expected dividend rate									0.00%
2014 Equity Plan [Member] | Restricted Stock [Member]
Number of restricted stock award granted	950	700
Number of common stock reserved					2,000		2,000
Stock-based compensation expense	$ 1,938	$ 742
2014 Equity Plan [Member] | Restricted Stock [Member] | General and Administrative Expenses [Member]
Stock-based compensation expense					$ 144	$ 62	$ 6		$ 82
2014 Equity Plan [Member] | Restricted Stock [Member] | Research and Development Expenses [Member]
Stock-based compensation expense					$ 25		$ 25
2014 Equity Plan [Member] | Restricted Stock [Member] | Employees [Member]
Number of restricted stock award granted		700		950
Vesting portion of stock		2014 Equity Plan, with such restricted stock awards vesting ratably on an annual basis over a three year period with an initial annual vesting date of March 15, 2020.		2014 Equity Plan, with such restricted stock awards vesting ratably on an annual basis over a three year period with an initial annual vesting date of May 1, 2021.
Restricted stock awards vested		234
2014 Equity Plan [Member] | Subsequent Event [Member] | Restricted Stock [Member]
Number of common stock reserved										10,000	8,000
2014 Equity Plan [Member] | Subsequent Event [Member] | Common Stock [Member]
Stock options granted			100
Stock option granted, contractual term			10 years
Stock option granted, weighted average exercise price			$ 2.04
Vesting portion of stock			Vesting ratably over twelve quarters commencing with the grant date quarter, with a weighted average exercise price of $2.04 per share of common stock of PAVmed Inc.
2018 Long-Term Incentive Equity Plan [Member]
Number of common stock issued								3
Weighted average fair value of stock options							$ 0.30		$ 0.39
Contractual term of stock options								10 years
2018 Long-Term Incentive Equity Plan [Member] | Non-employees [Member]
Weighted average fair value of stock options						$ 0.61			$ 0.61
Contractual term						9 years 1 month 6 days			9 years 1 month 6 days
Expected stock price volatility						62.00%			62.00%
Risk free interest rate						2.20%			2.20%
Expected dividend rate						0.00%			0.00%
2018 Stock Plan [Member]
Proceeds from issuance of common stock							$ 5

Stock-Based Compensation - Sche

Stock-Based Compensation - Schedule of Summarizes Information About Stock Options (Details) shares in Thousands	6 Months Ended
	Jun. 30, 2020$ / sharesshares
2014 Long Term Incentive Equity Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of Stock Options Outstanding, Beginning Balance | shares	5,204
Number of Stock Options, Granted | shares	1,345
Number of Stock Option, Exercised | shares
Number of Stock Option, Forfeited | shares
Number of Stock Options Outstanding, Ending Balance | shares	6,549
Number of Stock Options Vested and exercisable stock options | shares	4,016
Weighted Average Exercise Price, Beginning Balance | $ / shares	$ 2.68
Weighted Average Exercise Price, Granted | $ / shares	2.18
Weighted Average Exercise Price, Exercised | $ / shares
Weighted Average Exercise Price, Forfeited | $ / shares
Weighted Average Exercise Price, Ending Balance | $ / shares	2.58
Weighted Average Exercise Price, Vested and exercisable stock options | $ / shares	$ 313
Remaining Contractual Term (Years) stock options, Beginning	8 years 1 month 6 days
Remaining Contractual Term (Years) stock options, Exercised	9 years 9 months 18 days
Remaining Contractual Term (Years) stock options, Ending Balance	7 years 8 months 12 days
Remaining Contractual Term (Years), Vested and exercisable stock options	7 years 3 months 19 days
2018 Stock Plan [Member] | Lucid Diagnostics Inc [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of Stock Options Outstanding, Beginning Balance | shares	995
Number of Stock Options, Granted | shares
Number of Stock Option, Exercised | shares	3
Number of Stock Option, Forfeited | shares
Number of Stock Options Outstanding, Ending Balance | shares	992
Number of Stock Options Vested and exercisable stock options | shares	574
Weighted Average Exercise Price, Beginning Balance | $ / shares	$ 0.86
Weighted Average Exercise Price, Granted | $ / shares
Weighted Average Exercise Price, Exercised | $ / shares	1.50
Weighted Average Exercise Price, Forfeited | $ / shares
Weighted Average Exercise Price, Ending Balance | $ / shares	0.86
Weighted Average Exercise Price, Vested and exercisable stock options | $ / shares	$ 0.83
Remaining Contractual Term (Years) stock options, Beginning	9 years
Remaining Contractual Term (Years) stock options, Ending Balance	8 years 6 months
Remaining Contractual Term (Years), Vested and exercisable stock options	8 years 4 months 24 days

Stock-Based Compensation - Sc_2

Stock-Based Compensation - Schedule of Stock-Based Compensation Awards Granted (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2020	Jun. 30, 2019	Jun. 30, 2020	Jun. 30, 2019
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total stock-based compensation	$ 529	$ 388	$ 872	$ 847
General and Administrative Expenses [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total stock-based compensation	407	299	684	584
Research and Development Expenses [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total stock-based compensation	$ 122	$ 89	$ 188	$ 263

Stock-Based Compensation - Sc_3

Stock-Based Compensation - Schedule of Unrecognized Compensation Expense (Details) $ in Thousands	6 Months Ended
	Jun. 30, 2020USD ($)
2014 Long Term Incentive Equity Plan [Member] | Parent Company [Member] | Stock Options [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Unrecognized Expense	$ 2,269
Weighted Average Remaining Service Period	1 year 2 months 12 days
2014 Long Term Incentive Equity Plan [Member] | Parent Company [Member] | Restricted Stock [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Unrecognized Expense	$ 2,243
Weighted Average Remaining Service Period	2 years 7 months 6 days
2018 Long Term Incentive Equity Plan [Member] | Stock Options [Member] | Lucid Diagnostics Inc [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Unrecognized Expense	$ 75
Weighted Average Remaining Service Period	1 year 3 months 19 days

Stock-Based Compensation - Sc_4

Stock-Based Compensation - Schedule of Fair Values of Stock Options Granted Using Black-scholes Valuation Model Assumptions (Details)	6 Months Ended
	Jun. 30, 2020	Jun. 30, 2019
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected term of stock options (in years)		1 year 6 months 3 days
Expected stock price volatility		53.00%
Risk free interest rate		1.80%
Expected dividend yield		0.00%
2014 Long Term Incentive Equity Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected term of stock options (in years)	5 years 8 months 12 days	5 years 8 months 12 days
Expected stock price volatility	56.00%	50.00%
Risk free interest rate	2.00%	2.30%
Expected dividend yield	0.00%	0.00%
2018 Long Term Incentive Equity Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected term of stock options (in years)	5 years 2 months 12 days	5 years 8 months 12 days
Expected stock price volatility	60.00%	63.00%
Risk free interest rate	1.90%	2.50%
Expected dividend yield	0.00%	0.00%

Financial Instruments Fair Va_3

Financial Instruments Fair Value Measurements - Schedule of Financial Liabilities Measured at Fair Value on Recurring Basis (Details) - USD ($) $ in Thousands		Jun. 30, 2020	Dec. 31, 2019
Fair value of liability	[1]	$ 16,200	$ 8,139
November 2019 Senior Secured Convertible Notes [Member]
Fair value of liability	[1]	12,300	6,439
April 2020 Senior Secured Convertible Notes [Member]
Fair value of liability	[1]	3,900
December 2018 Senior Convertible Note [Member]
Fair value of liability	[1]		1,700
Fair Value, Inputs, Level 1 [Member]
Fair value of liability	[1]
Fair Value, Inputs, Level 1 [Member] | November 2019 Senior Secured Convertible Notes [Member]
Fair value of liability	[1]
Fair Value, Inputs, Level 1 [Member] | April 2020 Senior Secured Convertible Notes [Member]
Fair value of liability	[1]
Fair Value, Inputs, Level 1 [Member] | December 2018 Senior Convertible Note [Member]
Fair value of liability	[1]
Fair Value, Inputs, Level 2 [Member]
Fair value of liability	[1]
Fair Value, Inputs, Level 2 [Member] | November 2019 Senior Secured Convertible Notes [Member]
Fair value of liability	[1]
Fair Value, Inputs, Level 2 [Member] | April 2020 Senior Secured Convertible Notes [Member]
Fair value of liability	[1]
Fair Value, Inputs, Level 2 [Member] | December 2018 Senior Convertible Note [Member]
Fair value of liability	[1]
Fair Value, Inputs, Level 3 [Member]
Fair value of liability	[1]	16,200	8,139
Fair Value, Inputs, Level 3 [Member] | November 2019 Senior Secured Convertible Notes [Member]
Fair value of liability	[1]	12,300	6,439
Fair Value, Inputs, Level 3 [Member] | April 2020 Senior Secured Convertible Notes [Member]
Fair value of liability	[1]	$ 3,900
Fair Value, Inputs, Level 3 [Member] | December 2018 Senior Convertible Note [Member]
Fair value of liability	[1]		$ 1,700
[1]	As noted above, as presented in the fair value hierarchy table, Level-1 represents quoted prices in active markets for identical items, Level-2 represents significant other observable inputs, and Level-3 represents significant unobservable inputs. There were no transfers between the respective Levels during the six-month period ended June 30, 2020.

Financial Instruments Fair Va_4

Financial Instruments Fair Value Measurements - Schedule of Fair Value Assumption Used (Details) - $ / shares	6 Months Ended
	Jun. 30, 2020	Jun. 30, 2019
Required rate of return		11.10%
Conversion Price		$ 1.60
Expected term (years)		1 year 6 months 3 days
Volatility		53.00%
Risk free rate		1.80%
Dividend yield		0.00%
November 2019 Senior Secured Convertible Note Series A & Series B [Member]
Required rate of return	29.00%
Conversion Price	$ 1.60
Expected term (years)	1 year 2 months 30 days
Volatility	79.00%
Risk free rate	0.16%
Dividend yield	0.00%
April 2020 Senior Secured Convertible Notes [Member]
Required rate of return	68.00%
Conversion Price	$ 5
Expected term (years)	1 year 9 months 29 days
Volatility	65.00%
Risk free rate	0.16%
Dividend yield	0.00%

Outstanding Debt (Details Narra

Outstanding Debt (Details Narrative) - USD ($) $ / shares in Units, $ in Thousands	1 Months Ended	6 Months Ended
	Aug. 05, 2020	Jun. 30, 2020	Jun. 30, 2019	Dec. 31, 2019
Principal amount		$ 12,416		$ 8,692
Proceeds - issue of senior secured convertible notes		$ 6,300
Subsequent Event [Member] | Security Purchase Agreement [Member] | August 2020 Senior Secured Convertible Note [Member] | Investor [Member]
Principal amount	$ 7,750
Lender fee	750
Proceeds - issue of senior secured convertible notes	$ 7,000
Debt instrument maturity description	24 month
Interest rate	7.875%
Conversion price per share	$ 5

Outstanding Debt - Summary of O

Outstanding Debt - Summary of Outstanding Debt (Details) - USD ($) $ / shares in Units, $ in Thousands		6 Months Ended	12 Months Ended
		Jun. 30, 2020	Dec. 31, 2019
Face Value		$ 12,416	$ 8,692
Carrying Value		$ 16,200	$ 8,139
December 2018 Senior Convertible Note [Member]
Maturity Date	[1]	Dec. 31, 2020	Dec. 31, 2020
Stated Interest Rate	[1]	7.875%	7.875%
Conversion Price	[1]	$ 1.60	$ 1.60
Face Value	[1]		$ 1,692
Carrying Value	[1]		$ 1,700
November 2019 Senior Convertible Notes [Member]
Maturity Date	[2],[3]	Sep. 30, 2021	Sep. 30, 2021
Stated Interest Rate	[2],[3]	7.875%	7.875%
Conversion Price	[2],[3]	$ 1.60	$ 1.60
Face Value	[2],[3]	$ 8,305	$ 7,000
Carrying Value	[2],[3]	$ 12,300	$ 6,439
April 2020 Senior Secured Convertible Notes [Member]
Maturity Date	[4]	Apr. 30, 2022
Stated Interest Rate	[4]	7.875%
Conversion Price	[4]	$ 5
Face Value	[4]	$ 4,111
Carrying Value	[4]	$ 3,900
[1]	With respect to the December 2018 Senior Secured Convertible Note, in the six months ended June 30, 2020, approximately $1,692 of principal repayments and approximately $6 of non-installment payments were settled through the issuance of approximately 2,075 shares of common stock of the Company with a fair value of approximately $2,901 (with such fair value measured as the respective conversion date quoted closing price of the common stock of the Company). As of June 30, 2020, the December 2018 Senior Secured Debt balance was paid in full.
[2]	The November 2019 Senior Secured Convertible Note - Series B has a face value principal of approximately $7,000 and lender fees of approximately $700 (recognized as a current period expense), resulting in cash proceeds of approximately $6,300 received by the Company, with such cash proceeds delivered to the Company by the investors on March 30, 2020, at their election under the prepayment provisions of the Series B note of the November 2019 Senior Secured Convertible Note. Additionally, under a separate agreement, the Company incurred an expense of approximately $410 with respect to the placement agent advisory fee. The November 2019 Senior Secured Convertible Note - Series B has a contractual maturity date of September 30, 2021 and a stated interest rate of 7.875% per annum. The November 2019 Senior Secured Convertible Notes - Series A and Series B - have a stated interest rate of 7.875% per annum to the extent the investor has funded the cash proceeds of each such respective Series A and Series B. During the period November 4, 2019 to March 29, 2020, during which period the Series B was not funded by the investor, the Company incurred interest expense of 3.0% per annum on the Series B $7.0 million face value principal. The (cash) payment of such 3.0% interest on the $7.0 million face value principal resulted in the recognition of approximately $53 of interest expense during the period January 1, 2020 through March 29, 2020, with such interest expense included in other income (expense) in the accompanying (unaudited) condensed consolidated statement of operations. There was no such interest expense in the corresponding prior year period.
[3]	With respect to the November 2019 Senior Secured Convertible Note - Series A and Series B - in the six months ended June 30, 2020, approximately $5,695 of Accelerated and Bi-Monthly Installment principal repayments and approximately $242 of non-installment payments were settled through the issuance of approximately 3,753 shares of common stock of the Company with a fair value of approximately $8,671 (with such fair value measured as the respective conversion date quoted closing price of the common stock of the Company). Additionally, non-installment payments of approximately $138 were paid in cash in the same period. There were no such installment repayments nor non-installment payments in the corresponding prior year period. Subsequent to June 30, 2020, through August 11, 2020, approximately $480 of Accelerated and Bi-Monthly Installment principal repayments and approximately $4 of non-installment payments were settled through the issuance of approximately 303 shares of common stock of the Company with a fair value of approximately $[?] [PLACEHOLDER: To Be Updated /Computed in a.m. 8/12] (with such fair value measured as the respective conversion date quoted closing price of the common stock of the Company).
[4]	On April 30, 2020, the Company entered into a Security Purchase Agreement for the issue of a Senior Convertible Note with a face value principal of approximately $4,111 and lender fees of approximately $411 (recognized as a current period expense), resulting in $3,700 cash proceeds received by the Company referred to as the April 2020 Senior Convertible Note. Additionally, under a separate agreement, the Company incurred a current period expense of approximately $120 with respect to the placement agent advisory fee. The April 2020 Senior Convertible Note has a 24 month maturity, a 7.875% interest rate per annum, and a conversion price of $5.00 per share of the Company's common stock. On the maturity date, the Company will pay the holder in cash all remaining outstanding principal and unpaid interest thereon. In the six months ended June 30, 2020 non-installment payments in cash at the stated interest rate were made in the amount of approximately $54.

Outstanding Debt - Summary of_2

Outstanding Debt - Summary of Outstanding Debt (Details) (Parenthetical) - USD ($) $ / shares in Units, $ in Thousands		1 Months Ended			6 Months Ended		12 Months Ended
		Aug. 11, 2020	Apr. 30, 2020	Mar. 30, 2020	Jun. 30, 2020	Jun. 30, 2019	Dec. 31, 2019
Principal amount					$ 12,416		$ 8,692
Stock issued during the period conversion of senior secured convertible note
Proceeds - issue of senior secured convertible notes					6,300
Security Purchase Agreement [Member]
Advisory fee			$ 120
November 2019 Senior Convertible Notes [Member]
Principal amount	[1],[2]				$ 8,305		$ 7,000
Debt instrument maturity date	[1],[2]				Sep. 30, 2021		Sep. 30, 2021
Interest rate	[1],[2]				7.875%		7.875%
Conversion price per share	[1],[2]				$ 1.60		$ 1.60
November 2019 Senior Convertible Notes [Member] | Subsequent Event [Member] | Series A and Series B [Member]
Stock issued during the period conversion of senior secured convertible note, shares		303,000
Accelerated installment amount principal repayments - common stock		$ 618
November 2019 Senior Convertible Notes [Member] | Series A and Series B [Member]
Non-installment payments					$ 242
Additional non installment payments					138
Accelerated installment amount principal repayments - common stock					$ 5,695
November 2019 Senior Convertible Notes [Member] | Series A and Series B [Member] | Subsequent Event [Member]
Non-installment payments		4
Accelerated installment amount principal repayments - common stock		$ 480
November 2019 Senior Secured Convertible Notes [Member] | Series B [Member]
Lender fee				$ 700
Proceeds - issue of senior secured convertible notes				6,300
Advisory fee				$ 410
[1]	The November 2019 Senior Secured Convertible Note - Series B has a face value principal of approximately $7,000 and lender fees of approximately $700 (recognized as a current period expense), resulting in cash proceeds of approximately $6,300 received by the Company, with such cash proceeds delivered to the Company by the investors on March 30, 2020, at their election under the prepayment provisions of the Series B note of the November 2019 Senior Secured Convertible Note. Additionally, under a separate agreement, the Company incurred an expense of approximately $410 with respect to the placement agent advisory fee. The November 2019 Senior Secured Convertible Note - Series B has a contractual maturity date of September 30, 2021 and a stated interest rate of 7.875% per annum. The November 2019 Senior Secured Convertible Notes - Series A and Series B - have a stated interest rate of 7.875% per annum to the extent the investor has funded the cash proceeds of each such respective Series A and Series B. During the period November 4, 2019 to March 29, 2020, during which period the Series B was not funded by the investor, the Company incurred interest expense of 3.0% per annum on the Series B $7.0 million face value principal. The (cash) payment of such 3.0% interest on the $7.0 million face value principal resulted in the recognition of approximately $53 of interest expense during the period January 1, 2020 through March 29, 2020, with such interest expense included in other income (expense) in the accompanying (unaudited) condensed consolidated statement of operations. There was no such interest expense in the corresponding prior year period.
[2]	With respect to the November 2019 Senior Secured Convertible Note - Series A and Series B - in the six months ended June 30, 2020, approximately $5,695 of Accelerated and Bi-Monthly Installment principal repayments and approximately $242 of non-installment payments were settled through the issuance of approximately 3,753 shares of common stock of the Company with a fair value of approximately $8,671 (with such fair value measured as the respective conversion date quoted closing price of the common stock of the Company). Additionally, non-installment payments of approximately $138 were paid in cash in the same period. There were no such installment repayments nor non-installment payments in the corresponding prior year period. Subsequent to June 30, 2020, through August 11, 2020, approximately $480 of Accelerated and Bi-Monthly Installment principal repayments and approximately $4 of non-installment payments were settled through the issuance of approximately 303 shares of common stock of the Company with a fair value of approximately $[?] [PLACEHOLDER: To Be Updated /Computed in a.m. 8/12] (with such fair value measured as the respective conversion date quoted closing price of the common stock of the Company).

Outstanding Debt - Schedule of

Outstanding Debt - Schedule of Senior Convertible Note Estimated Fair Value (Details) - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2020	Jun. 30, 2019
Fair Value - Beginning	$ 8,139
Face value principal - issue date	4,111
Fair value adjustment at issue date	(411)
Installment repayments - cash	2,189
Installment repayments - common stock	(5,745)
Non-installment repayments - common stock	(244)
Non-installment repayments - cash	(54)
Change in fair value	(2,120)
Fair Value - Ending	16,200
December 2018 Senior Secured Convertible Note [Member]
Fair Value - Beginning	1,700	$ 7,903
Fair value adjustment at issue date
Installment repayments - cash		(279)
Installment repayments - common stock	(1,698)	(1,554)
Non-installment repayments - common stock
Non-installment repayments - cash
Change in fair value	(2)	720
Fair Value - Ending		6,790
November 2019 Senior Secured Convertible Note Series A & Series B [Member] | Series A and Series B [Member]
Fair Value - Beginning	6,439
Fair value adjustment at issue date	7,000
Installment repayments - cash	2,600
Installment repayments - common stock	(5,695)
Non-installment repayments - common stock	(242)
Non-installment repayments - cash	(138)
Change in fair value	2,336
Fair Value - Ending	12,300
November 2019 Senior Secured Convertible Note Series A & Series B [Member] | Series B [Member]
Lender Fee	(700)
April 2020 Senior Secured Convertible Notes [Member]
Fair Value - Beginning
Fair value adjustment at issue date	4,111
Installment repayments - cash	(411)
Installment repayments - common stock
Non-installment repayments - common stock
Non-installment repayments - cash	(54)
Change in fair value	254
Fair Value - Ending	3,900
Lender Fee	(411)
Other Income (Expense) [Member]
Fair Value - Beginning
Installment repayments - cash	(2,189)
Change in fair value	(2,588)	(720)
Fair Value - Ending	(4,777)	$ (720)
Other Income (Expense) - Change in fair value - Senior Secured Convertible Notes and Senior Convertible Notes	$ (5,888)

Cares Act Paycheck Protection_2

Cares Act Paycheck Protection Program Loan (Details Narrative) - USD ($) $ in Thousands	Apr. 08, 2020	Jun. 30, 2020	Dec. 31, 2019
Current portion - cares act paycheck protection program note payable		$ 150
Non current portion - cares act paycheck protection program note payable		$ 150
Loan Agreement [Member] | JP Morgan Chase, N.A [Member] | PPP Loan [Member]
Proceeds from loan	$ 300
Debt instrument maturity date	Apr. 8, 2022
Interest rate	1.00%
Current portion - cares act paycheck protection program note payable	$ 150
Non current portion - cares act paycheck protection program note payable	$ 150

Preferred Stock (Details Narrat

Preferred Stock (Details Narrative) - Series B Convertible Preferred Stock [Member] - USD ($) $ in Thousands	1 Months Ended	6 Months Ended
	Jul. 31, 2020	Jun. 30, 2020	Mar. 31, 2020	Dec. 31, 2019
Dividend payable			$ 140	$ 140
Additional shares of dividend		47,000
Subsequent Event [Member]
Dividend payable	$ 71
Additional shares of dividend	24,000

Stockholders' Equity, Common _3

Stockholders' Equity, Common Stock Purchase Warrants, and Noncontrolling Interest (Details Narrative) - USD ($) $ / shares in Units, $ in Thousands	6 Months Ended
	Jun. 30, 2020	Jun. 30, 2019	Jul. 24, 2020	Dec. 31, 2019
Common stock purchase warrants	17,250,000	18,449,000
Warrants exercise price	$ 1.68	$ 1.57
Proceeds from warrants exercised	$ 12
Common shares authorized	150,000,000			150,000,000
Common Stock [Member]
Common shares authorized	50,000		100,000
Series S Warrants [Member]
Warrants exercised	1,199,000
Proceeds from warrants exercised	$ 12

Stockholders' Equity, Common _4

Stockholders' Equity, Common Stock Purchase Warrants, and Noncontrolling Interest - Schedule of Noncontrolling Interest (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended		12 Months Ended
	Jun. 30, 2020	Jun. 30, 2019	Jun. 30, 2020	Jun. 30, 2019	Dec. 31, 2019
NCI - equity (deficit) - beginning of period			$ (814)
Net loss attributable to NCI	$ (266)	$ (145)	(702)	$ (314)
Stock-based compensation expense - Lucid Diagnostics Inc 2018 Equity Plan	513	356	840	706
NCI - equity (deficit) - end of period	(1,485)		(1,485)		$ (814)
Non-controlling Interest [Member]
NCI - equity (deficit) - beginning of period			(814)	(162)	(162)
Stock-based compensation expense - Lucid Diagnostics Inc 2018 Equity Plan
NCI - equity (deficit) - end of period	$ (1,485)		(1,485)		(814)
Non-controlling Interest [Member] | Solys Diagnostics Inc. [Member]
Minority Interest investment in Solys Diagnostics Inc					889
Minority Interest share subscription receivable - Solys Diagnostics Inc.					(889)
Net loss attributable to NCI			(62)		(10)
Non-controlling Interest [Member] | Lucid Diagnostics Inc [Member]
Minority Interest Lucid Diagnostics Inc. 2018 Equity Plan stock option exercise			5
Net loss attributable to NCI			(640)		(801)
Stock-based compensation expense - Lucid Diagnostics Inc 2018 Equity Plan			$ 26		$ 159

Loss Per Share - Schedule of Co

Loss Per Share - Schedule of Comparison of Basic and Fully Diluted Net Loss Per Share (Details) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2020	Jun. 30, 2019	Jun. 30, 2020	Jun. 30, 2019
Earnings Per Share [Abstract]
Net loss - before noncontrolling interest	$ (5,844)	$ (3,739)	$ (20,755)	$ (7,443)
Net loss attributable to noncontrolling interest	266	145	702	314
Net loss - as reported, attributable to PAVmed Inc.	(5,578)	(3,594)	(20,053)	(7,129)
Series B Convertible Preferred Stock dividends:	(71)	(66)	(141)	(132)
Net loss attributable to PAVmed Inc. common stockholders	$ (5,649)	$ (3,660)	$ (20,194)	$ (7,261)
Weighted average common shares outstanding basic and diluted	44,781	27,606	44,140	27,344
Basic and diluted - Net loss - as reported, attributable to PAVmed Inc.	$ (0.12)	$ (0.13)	$ (0.45)	$ (0.26)
Basic and diluted - Net loss attributable to PAVmed Inc. common stockholders	$ (0.13)	$ (0.13)	$ (0.46)	$ (0.27)

Loss Per Share - Schedule of An

Loss Per Share - Schedule of Antidilutive Securities Excluded from Computation of Diluted Earnings Per Share (Details) - shares shares in Thousands	6 Months Ended
	Jun. 30, 2020	Jun. 30, 2019
Antidilutive securities excluded from computation of diluted weighted shares outstanding	26,448	24,220
PAVmed Inc. 2014 Equity Plan Stock Options and Restricted Awards [Member]
Antidilutive securities excluded from computation of diluted weighted shares outstanding	7,965	5,804
Unit Purchase Options as to Shares of common stock [Member]
Antidilutive securities excluded from computation of diluted weighted shares outstanding	53	53
Unit Purchase Options as to Shares Underlying Series Z Warrants [Member]
Antidilutive securities excluded from computation of diluted weighted shares outstanding	53	53
Series Z Warrants [Member]
Antidilutive securities excluded from computation of diluted weighted shares outstanding	16,815	16,815
Series W Warrants [Member]
Antidilutive securities excluded from computation of diluted weighted shares outstanding	382	382
Series B Convertible Preferred Stock [Member]
Antidilutive securities excluded from computation of diluted weighted shares outstanding	1,180	1,113